Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 13M | 19M | 18M | 13M | 12M |
| Gross Profit | 5M | 3M | -5M | 3M | 5M |
| Operating Income | -3M | -2M | -9M | -5M | -4M |
| EBITDA | 632K | 314K | -9M | -5M | -3M |
| Net Income | -145K | -1M | -13M | -18M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00555
+11.00% today
1Y Change
+31.58%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
1933 Industries Inc. (TGIFF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.01 and up 31.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -34.9%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -34.9%, EPS +100.0%, free cash flow +50.1% with operating margin -6.4% and ROIC -7.8%. Valuation is more restrained than many high-expectation growth names at P/E 16.1 and price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TGIFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGIFF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TGIFF Max Drawdown
-70.71%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TGIFF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.0M
-4.5% YoY
FY Net Income
-$6.5M
+63.7% YoY
Free Cash Flow
-$5.1M
-0.4% YoY
Revenue Growth
-34.9%
EPS Growth
+100.0%
Gross Margin
13.6%
Net Margin
2.8%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 13M | 19M | 18M | 13M | 12M |
| Gross Profit | 5M | 3M | -5M | 3M | 5M |
| Operating Income | -3M | -2M | -9M | -5M | -4M |
| EBITDA | 632K | 314K | -9M | -5M | -3M |
| Net Income | -145K | -1M | -13M | -18M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 546K | 449K | 1M | 363K | 4M |
| Total Assets | 12M | 17M | 18M | 29M | 45M |
| Total Liabilities | 21M | 22M | 23M | 21M | 20M |
| Shareholder Equity | -5M | -4M | -4M | 9M | 26M |
| Total Debt | 18M | 17M | 18M | 18M | 18M |
| Net Debt | 17M | 16M | 16M | 17M | 13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
+8.3% YoY
Capital Expenditures
456K
-2961.2% YoY
Free Cash Flow
5M
-0.4% YoY
Key ratios
Gross Margin
13.6%
Operating Margin
-6.4%
Net Margin
2.8%
ROE
-11.1%
Debt / Equity
-4.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.